Senior Director​/Vice President, Program Team Leader, Neurology and Pipeline Assets

Blue Rock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary CELL+GENE™ platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases. Founded in 2016, Blue Rock is at the forefront of the convergence of cell biology and genetic engineering.

Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.

Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies. We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options.

Blue Rock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Utilizing our proprietary platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases. Founded in 2016, Blue Rock is at the forefront of the convergence of cell biology and genetic engineering.

Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.

The Senior Director/Vice President, Program Team Leader is the single point of accountability for the strategy, value creation, and delivery of a priority Blue Rock asset. The initial assignment is expected to be our next-generation cell therapy for Parkinson’s disease. Asset responsibility will evolve with portfolio priorities. This leader will align senior functional experts around a clear asset vision, integrated development plan, and decisive path to execution.

The role requires an accomplished drug developer who can operate credibly across science, technical operations, development, governance, and external stakeholders in a lean, matrixed environment. The role reports to the Chief Executive Officer until the program reaches an established transition point in late-stage development.

• Asset Strategy and Development—Own the integrated asset strategy, Target Product Profile, and development plan from IND-enabling work through proof of concept and beyond. Integrate clinical, regulatory, CMC, nonclinical, safety, commercial, and evidence-generation strategies into a coherent value-creation plan. Establish decision criteria, scenarios, and off-ramps that enable timely, evidence-based investment decisions. Maintain a current view of the scientific, competitive, and market landscape and translate it into program implications.
• Cross-Functional Leadership and Delivery—Lead the cross-functional Program Team and create clear accountability for functional deliverables and overall program outcomes. Drive prioritization, resolve barriers, and secure the resources required to meet critical milestones, including DA02 IND submission and first-in-human readiness. Own the integrated timeline, budget, resource plan, and risk profile in partnership with Program Management and Finance. Ensure compliant, inspection-ready execution with uncompromising…